A Phase 2 combination study of Betalutin and rituximab in iNHL patients
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms ARCHER-1
- 27 Feb 2018 According to a Nordic Nanovector media release, the final design of this trial was completed.
- 28 Nov 2017 New trial record
- 22 Nov 2017 According to a Nordic Nanovector media release, the company is planning to start this trial in 2H 2017.